Randomized phase II trial of oral vinorelbine (OV) and cisplatin (P) followed by maintenance with single-agent OV versus (vs) gemcitabine (GEM) and P followed by maintenance with single-agent GEM as first-line chemotherapy (CT) in locally advanced (LA) or metastatic non-small-cell lung cancer (NSCLC) patients (pts) with squamous (sq) histological type.